Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beam TherapeuticsMEX:BEAM 66 1-Year Share Buyback Ratio is -2.50 as of Jun. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN408.33 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,110 Biotechnology companies, Beam Therapeutics ranks better than 72.97% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Beam Therapeutics's current 1-Year Share Buyback Ratio was -2.50%.
MEX:BEAM's 1-Year Share Buyback Ratio is ranked better than 72.97% of 1110
companies
in the Biotechnology industry
Industry Median: -14.55
vs MEX:BEAM: -2.50
Beam Therapeutics (MEX:BEAM) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Beam Therapeutics 1-Year Share Buyback Ratio Related Terms
MEX:BEAM vs KOD, TARS, VERA: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Beam Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -2.50 mean?
Beam Therapeutics (MEX:BEAM) has a 1-Year Share Buyback Ratio of -2.50 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Beam Therapeutics and its competitors. According to the industry distribution chart, Beam Therapeutics ranks #300 out of 1110 companies in the Biotechnology industry, placing it in the top 27%.
Is Beam Therapeutics' 1-Year Share Buyback Ratio too high?
Beam Therapeutics' current 1-Year Share Buyback Ratio is -2.50. Based on the distribution chart, Beam Therapeutics ranks #300 out of 1110 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' 1-Year Share Buyback Ratio compare to KOD and TARS?
According to the Biotechnology industry distribution chart, Beam Therapeutics ranks #300 out of 1110 companies for 1-Year Share Buyback Ratio. This puts Beam Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Beam Therapeutics and its competitors. Beam Therapeutics's current 1-Year Share Buyback Ratio is -2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN408.33, compared to a current price of MXN454.00 — trading 11.2% above its estimated fair value. The current 1-Year Share Buyback Ratio is -2.50. Beam Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current 1-Year Share Buyback Ratio is -2.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN454.00 is trading 11.2% above its estimated GF Value™ of MXN408.33.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for MEX:BEAM:
1-Year Share Buyback Ratio: -2.50
GF Value™: MXN408.33 vs. price of MXN454.00 (11.2% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score
Get the complete analysis for MEX:BEAM
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
